The QE2 Study: Effects of CoEnzyme Q10 in Early Parkinson's Disease, was an NINDS funded pilot study of 80 subjects with early untreated Parkinson's disease (PD). The PI was Clifford Shults, MD at UCSD. It was a randomized, double-blind, parallel group comparison of three doses of coenzyme Q10 (CoQ10) (300, 600 and 1200 mg/day) versus placebo in patients and do not yet require treatment with levodopa.  
                                                                                                              

Below find the following study documents: 

                                1. QE2 Protocol Synopsis    

                                2. QE2 Schedule of Activites (SOA)

                                3. QE2 Data Dictionary 
                                4. Instructions for downloading data
                                5. Links to published papers

Shults CW, Oakes D, Kieburtz K, Beal F, Hass R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, and the Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.

Only registered users who have been approved to download the QE2 database are permitted to view/access the database files below (you must Login to access the data):